Forum Markets, Incorporated

NasdaqCM:FRMM Stock Report

Market Cap: US$63.3m

Forum Markets Future Growth

Future criteria checks 5/6

Forum Markets is forecast to grow earnings and revenue by 127.1% and 58% per annum respectively. EPS is expected to grow by 137.3% per annum. Return on equity is forecast to be 4.1% in 3 years.

Key information

127.1%

Earnings growth rate

137.25%

EPS growth rate

Biotechs earnings growth29.1%
Revenue growth rate58.0%
Future return on equity4.14%
Analyst coverage

Low

Last updated14 Aug 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 26

FRMM: Share Repurchase And Special Committee Review Will Reshape Future Profile

Analysts have lifted the Forum Markets price target to $9 from $5, citing the company's first earnings report as a full real world asset tokenization platform, its $24.9M cash-funded repurchase and retirement of about 5.8M shares, the formation of a special committee to review strategic alternatives, and the launch of a fourth origination vertical. Analyst Commentary Analyst coverage of Forum Markets focuses on how the company is positioning itself as a full real world asset tokenization platform, how it is using its cash balance, and what the current review of strategic alternatives could mean for valuation and execution risk.
New Narrative • Apr 08

Ethereum Yield And Tokenized Assets Will Drive Future Forum Markets Upside

Catalysts About Forum Markets Forum Markets operates a technology platform that connects traditional finance with decentralized finance using Ethereum, combining ETH based yield generation with infrastructure for trading tokenized real world assets. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Jul 18

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences (NASDAQ:ATNF) stated Monday the company has signed a definitive $6.5M stock offering deal with a healthcare-focused U.S. institutional investor.  The deal will include the issue of 6.13M common shares and warrants to purchase up to 6.13M additional share, at combined $1.06 per unit. Warrants have an exercise price of $1.06 per share with expiry of 5 years. The clinical-stage biotechnology said it intends to use the net proceeds for research and development expenses and general corporate purposes. Closing of the offering is expected on July 20, 2022. Stock is down 9% premarket, Monday, to trade at $1.04 vs. 52-week trading range of $0.80 to $9.05. Earlier: 180 Life Sciences falls after updates on regulatory path for anti-fibrosis therapy
Seeking Alpha • Sep 08

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitations of bioavailability in CBD; advantages of synthetic CBD.
Analysis Article • Feb 17

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

The big shareholder groups in 180 Life Sciences Corp. ( NASDAQ:ATNF ) have power over the company. Large companies...

Earnings and Revenue Growth Forecasts

NasdaqCM:FRMM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028511330301
12/31/202742-1023232
12/31/202618-96-70-232
6/30/202611-530-73-57N/A
3/31/20269-519-62-46N/A
12/31/20257-444-26-26N/A
9/30/20254-221-19-19N/A
6/30/2025N/A-13-3-3N/A
3/31/2025N/A-12-1-1N/A
12/31/2024N/A-11-1-1N/A
9/30/2024N/A-3-3-3N/A
6/30/2024N/A-13-4-4N/A
3/31/2024N/A-16-8-8N/A
12/31/2023N/A-20-11-11N/A
9/30/2023N/A-40-12-12N/A
6/30/2023N/A-52-14-14N/A
3/31/2023N/A-45-14-14N/A
12/31/2022N/A-39-12-12N/A
9/30/2022N/A-16-14-14N/A
6/30/2022N/A24-15-15N/A
3/31/2022N/A-3-15-15N/A
12/31/2021N/A-20-19-19N/A
9/30/2021N/A-30-18-18N/A
6/30/2021N/A-50-14-14N/A
3/31/2021N/A-26-10-10N/A
12/31/2020N/A-12-4-4N/A
9/30/2020N/A-29-3-3N/A
6/30/2020N/A-28-3-3N/A
3/31/2020N/A-28N/A-3N/A
12/31/2019N/A-25N/A-3N/A
9/30/2019N/A-4N/A-2N/A
6/30/2019N/A-6N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FRMM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).

Earnings vs Market: FRMM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: FRMM is expected to become profitable in the next 3 years.

Revenue vs Market: FRMM's revenue (58% per year) is forecast to grow faster than the US market (13.4% per year).

High Growth Revenue: FRMM's revenue (58% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FRMM's Return on Equity is forecast to be low in 3 years time (4.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/18 10:30
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Forum Markets, Incorporated is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Nazibur RahmanMaxim Group
Brendan Michael McCarthySidoti & Company, LLC